Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
By Dennis Thompson HealthDay ReporterWEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
Columnist Ben Hofmeister never feels he's quite ready for the unpredictability of MS, which makes planning for life's challenges hard.
French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...
If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...
People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...
The faster patients can be diagnosed with multiple sclerosis, the sooner they can begin taking the powerful medications that ...
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
News-Medical.Net on MSN
Lipoic acid shows limited benefit in progressive multiple sclerosis
The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...
Multiple sclerosis can affect many areas of your daily life, including dental care. Symptoms of multiple sclerosis and the medications you take for these symptoms can lead to an increased need for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback